Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DDX6_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DDX6_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DDX6_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DDX6_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DDX6_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DDX6_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DDX6_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003406322 | Oral cavity | EOLP | stress granule assembly | 11/2218 | 26/18723 | 8.86e-05 | 1.04e-03 | 11 |
GO:006096422 | Oral cavity | EOLP | regulation of gene silencing by miRNA | 15/2218 | 49/18723 | 3.73e-04 | 3.38e-03 | 15 |
GO:200063723 | Oral cavity | EOLP | positive regulation of gene silencing by miRNA | 11/2218 | 30/18723 | 3.99e-04 | 3.56e-03 | 11 |
GO:006014822 | Oral cavity | EOLP | positive regulation of posttranscriptional gene silencing | 11/2218 | 31/18723 | 5.53e-04 | 4.71e-03 | 11 |
GO:006014723 | Oral cavity | EOLP | regulation of posttranscriptional gene silencing | 15/2218 | 52/18723 | 7.52e-04 | 6.05e-03 | 15 |
GO:006096623 | Oral cavity | EOLP | regulation of gene silencing by RNA | 15/2218 | 53/18723 | 9.35e-04 | 7.11e-03 | 15 |
GO:006096813 | Oral cavity | EOLP | regulation of gene silencing | 20/2218 | 81/18723 | 9.93e-04 | 7.46e-03 | 20 |
GO:00339629 | Oral cavity | EOLP | P-body assembly | 8/2218 | 21/18723 | 1.87e-03 | 1.21e-02 | 8 |
GO:001603233 | Oral cavity | NEOLP | viral process | 101/2005 | 415/18723 | 1.08e-15 | 5.85e-13 | 101 |
GO:001905834 | Oral cavity | NEOLP | viral life cycle | 77/2005 | 317/18723 | 3.13e-12 | 5.82e-10 | 77 |
GO:000641734 | Oral cavity | NEOLP | regulation of translation | 97/2005 | 468/18723 | 9.94e-11 | 1.05e-08 | 97 |
GO:000961531 | Oral cavity | NEOLP | response to virus | 80/2005 | 367/18723 | 3.70e-10 | 3.14e-08 | 80 |
GO:003052231 | Oral cavity | NEOLP | intracellular receptor signaling pathway | 61/2005 | 265/18723 | 5.22e-09 | 2.87e-07 | 61 |
GO:005160731 | Oral cavity | NEOLP | defense response to virus | 57/2005 | 265/18723 | 1.97e-07 | 6.55e-06 | 57 |
GO:014054631 | Oral cavity | NEOLP | defense response to symbiont | 57/2005 | 265/18723 | 1.97e-07 | 6.55e-06 | 57 |
GO:003210323 | Oral cavity | NEOLP | positive regulation of response to external stimulus | 81/2005 | 427/18723 | 2.04e-07 | 6.74e-06 | 81 |
GO:000283131 | Oral cavity | NEOLP | regulation of response to biotic stimulus | 65/2005 | 327/18723 | 5.93e-07 | 1.74e-05 | 65 |
GO:001982721 | Oral cavity | NEOLP | stem cell population maintenance | 34/2005 | 131/18723 | 6.89e-07 | 1.93e-05 | 34 |
GO:009872721 | Oral cavity | NEOLP | maintenance of cell number | 34/2005 | 134/18723 | 1.21e-06 | 3.13e-05 | 34 |
GO:003406331 | Oral cavity | NEOLP | stress granule assembly | 11/2005 | 26/18723 | 3.46e-05 | 5.12e-04 | 11 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DDX6 | SNV | Missense_Mutation | | c.602N>C | p.Gly201Ala | p.G201A | P26196 | protein_coding | deleterious(0) | possibly_damaging(0.824) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
DDX6 | SNV | Missense_Mutation | | c.1104N>C | p.Met368Ile | p.M368I | P26196 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
DDX6 | SNV | Missense_Mutation | | c.952N>A | p.Glu318Lys | p.E318K | P26196 | protein_coding | deleterious(0.04) | possibly_damaging(0.665) | TCGA-D8-A1XJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
DDX6 | SNV | Missense_Mutation | | c.1198A>T | p.Ile400Leu | p.I400L | P26196 | protein_coding | deleterious(0) | possibly_damaging(0.847) | TCGA-D8-A1XV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DDX6 | insertion | Frame_Shift_Ins | novel | c.38_39dupGT | p.Leu14ValfsTer9 | p.L14Vfs*9 | P26196 | protein_coding | | | TCGA-A7-A26F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
DDX6 | insertion | Frame_Shift_Ins | novel | c.42_43insAGGCAGGTAGATCACGAGGTCAAAAGTTTGAGGC | p.Ser15ArgfsTer50 | p.S15Rfs*50 | P26196 | protein_coding | | | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DDX6 | insertion | Frame_Shift_Ins | novel | c.962_963insCTTTAGAAGACTTACTCTGGCACTCATAC | p.Lys321AsnfsTer24 | p.K321Nfs*24 | P26196 | protein_coding | | | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
DDX6 | SNV | Missense_Mutation | novel | c.220N>G | p.Lys74Glu | p.K74E | P26196 | protein_coding | tolerated(0.46) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DDX6 | insertion | Frame_Shift_Ins | novel | c.1036_1037insTAGAA | p.Arg346LeufsTer7 | p.R346Lfs*7 | P26196 | protein_coding | | | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
DDX6 | insertion | Nonsense_Mutation | novel | c.1035_1036insGGAGAATGA | p.Gln345_Arg346insGlyGluTer | p.Q345_R346insGE* | P26196 | protein_coding | | | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |